Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026
Change in working capital of -$427K in Q2 FY2026
Q2 FY2026 change in working capital was -$427K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 1.36M USD
- Year-over-year change
- —
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.36M | — |
Change in Working Capital vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's FY2025 change in working capital of $1.36M is the smallest of the 5 companies compared; the peer median is $2.6M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
DMRADamora Therapeutics, Inc. | LTM Jun 2024 | $9.96M | — | +15.4% | — |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $8.4M | +309.6% | +18.4% | — |
| LTM Mar 2026 | $6.61M | -41.7% | -46.1% | 36.5% | |
| LTM Mar 2026 | $1.41M | -73.3% | +64.8% | 164.0% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $1.36M | — | — | — |
| Peer median (excluding COAG) | $2.6M | -41.7% | +16.9% | 100.3% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (63.91M) |
| Depreciation & Amortization | 304K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.01M |
| Change in Working Capital | 1.36M |
| Accounts Receivables | 0 |
| Inventory | 0 |
| Accounts Payables | 2.58M |
| Other Working Capital | (1.22M) |
| Other Non-Cash Items | (1.23M) |
| Operating Cash Flow | (61.48M) |
| Capital Expenditures | (16K) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (252.5M) |
| Sales of Investments | 171.03M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (81.48M) |
| Debt Repayment | (120K) |
| Common Stock Issued | 0 |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | 0 |
| Financing Cash Flow | 156.3M |
| Effect of Forex Changes | 223K |
| Net Change in Cash | 13.57M |
| Free Cash Flow | (61.49M) |
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.